Sarepta Therapeutics Inc.
Commercial-stage biopharma developing RNA‑targeted and gene therapies for rare neuromuscular diseases, with approved EXONDYS 51/53 and pipeline AMONDYS 45, ELEVIDYS, and SRP‑9003, backed by key collaborations with Roche, Arrowhead, and universities.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 1,372
- HQ: Cambridge
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.